StockMarketWire.com - Scancell Holdings said a patent for its DNA ImmunoBody technology has now been granted in Europe.

The European patent, number 2134357, granted by the European Patent Office, covers Scancell's DNA ImmunoBody platform technology and was key to the protection of the Company's pipeline of ImmunoBody vaccines, including lead candidates, SCIB1 and SCIB2.

On issuance, this patent would extend coverage of Scancell's intellectual property into another important market for Scancell. Counterparts to this patent had already been granted in the US, Australia and Japan.

The European patent covered the following countries: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Sweden and Turkey.




Story provided by StockMarketWire.com